Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant low-dose radiotherapy + SBRT followed by tislelizumab plus platinum doublet chemotherapy for resectable stage IIA-IIIB NSCLC
ChiCTR2500097220Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab, carboplatin and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
tislelizumabcarboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500097220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097220.